PARP Inhibitors What Do We know PARP Inhibitors What Do We Know cont PARP Inhibitors What Dont We Know SOLO1 Study Rationale and Design a Primary Endpoint and Other R esults Time to Second Progression or Death ID: 750514
Download Presentation The PPT/PDF document "PARP Inhibitors This program will includ..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
PARP InhibitorsSlide2Slide3
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.Slide4
PARP Inhibitors: What Do We know?Slide5
PARP Inhibitors: What Do We Know? (cont)Slide6
PARP Inhibitors: What Don't We Know ?Slide7
SOLO-1: Study Rationale and Design[a]Slide8
Primary Endpoint and Other R
esultsSlide9
Time to Second Progression or Death (PFS2)Slide10
SOLO-1 ConclusionsSlide11
PAOLA-1: Phase 3 Trial of Olaparib Plus Bevacizumab
vs Placebo Plus Bevacizumab as Maintenance Treatment in Advanced Ovarian CancerSlide12
VELIA: Phase 3 Trial of Veliparib With Carboplatin and Paclitaxel as Continuous MaintenanceSlide13
PRIMA: Phase 3 Trial of Niraparib vs Placebo as Maintenance Treatment in Advanced Ovarian CancerSlide14
PARP Inhibitors as Maintenance TherapySlide15
QUADRA Slide16
Updated Analysis of QUADRASlide17
ORR in Biomarker-Defined, Response-Evaluable PopulationSlide18
Strategies for the FutureSlide19
Randomized Phase 2 Trial Combining Cediranib and Olaparib in Platinum-Sensitive Recurrent Ovarian CancerSlide20
Phase 3 NCI GY004
PFS by BRCA Status Slide21
NCI GY004 (Platinum Sensitive)Slide22
NCI GY005 (COCOS/Platinum Resistant)Slide23
ICON9: Randomized Trial of Cediranib and Olaparib Maintenance in Relapsed Platinum-Sensitive
Ovarian Cancer Slide24
MEDIOLA: Phase 2 Basket Study of Olaparib + PDL1 Antibody (Durvalumab) in
BRCA
m-Positive Relapsed Ovarian CancerSlide25
TOPACIO: Single-Arm Trial of PARP Inhibitor (Niraparib) + Anti-PDL1 (Pembrolizumab) Slide26
JAVELIN Ovarian 100 PARPSlide27
ATHENA Study DesignSlide28
Which First-Line Trials Are Enrolling Patients? Slide29
Take-Home MessagesSlide30
Take-Home Messages (cont)Slide31
Take-Home Messages (cont)Slide32